Incyte Corporation

Industry

  • Biotechnology
    • Drug Discovery Technologies
      • ADMET
      • Genomics-Proteomics
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Vaccines

Other Names/Subsidiaries

  • Escient Pharmaceuticals Inc.
  • Maxia Pharmaceuticals, Inc.
  • Villaris Therapeutics, Inc.
  • Escient Pharmaceuticals
  • Villaris Therapeutics
See more in Biomedtracker

Latest on Incyte Corporation

Scrip

What Incyte Investors Expect From New CEO Bill Meury

 
• By Andrew McConaghie

Incyte’s share price has risen after the company announced biopharma veteran Bill Meury as it new CEO, with investors anticipating a strategy refocus or even plans to put it up for sale. The move, rev

Scrip

Kymera Inks CDK2 Deal With Gilead

 
• By Alaric DeArment

Who: Kymera Therapeutics with Gilead Sciences What: On June 25, Kymera announced a deal with Gilead for molecular glue degraders targeting CDK2. Why: While potent anti-cancer drugs, traditional C

Scrip

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC

 
• By Joseph Haas, Lisa Takagi, Sushmita Panda, and Xu Hu

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. SunRock, Escugen Partner To Develo

Scrip

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

It is early days but Incyte has caught the eye of analysts with promising first data from two studies of its first-in-class monoclonal antibody for patients with mutant calreticulin (mutCALR)-expressi